

**SIGLEC1 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP1621a****Specification**

---

**SIGLEC1 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [Q9BZZ2](#)**SIGLEC1 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 6614**Other Names**

Sialoadhesin, Sialic acid-binding Ig-like lectin 1, Siglec-1, CD169, SIGLEC1, SN

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP1621a](/product/products/AP1621a) was selected from the N-term region of human SIGLEC1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SIGLEC1 Antibody (N-term) Blocking Peptide - Protein Information****Name** SIGLEC1**Synonyms** SN**Function**

Macrophage-restricted adhesion molecule that mediates sialic- acid dependent binding to lymphocytes, including granulocytes, monocytes, natural killer cells, B-cells and CD8 T-cells. Plays a crucial role in limiting bacterial dissemination by engaging sialylated bacteria to promote effective phagocytosis and antigen presentation for the adaptive immune response (PubMed: [12940982](http://www.uniprot.org/citations/12940982), PubMed: [33489013](http://www.uniprot.org/citations/33489013)). Mediates the uptake of various enveloped viruses via sialic acid recognition and subsequently induces the formation of intracellular compartments filled with virions (VCCs)(PubMed: [28129379](http://www.uniprot.org/citations/28129379)). In turn, enhances macrophage-to-T-cell transmission of several viruses including HIV-1 or SARS-CoV-2

(PubMed:<a href="http://www.uniprot.org/citations/28129379" target="\_blank">28129379</a>, PubMed:<a href="http://www.uniprot.org/citations/34782760" target="\_blank">34782760</a>). Acts as an endocytic receptor mediating clathrin dependent endocytosis. Preferentially binds to alpha-2,3-linked sialic acid (PubMed:<a href="http://www.uniprot.org/citations/12940982" target="\_blank">12940982</a>). Binds to SPN/CD43 on T-cells (By similarity). May play a role in hemopoiesis. Plays a role in the inhibition of antiviral innate immune by promoting TBK1 degradation via TYROBP and TRIM27-mediated ubiquitination (PubMed:<a href="http://www.uniprot.org/citations/26358190" target="\_blank">26358190</a>).

#### **Cellular Location**

[Isoform 1]: Cell membrane; Single-pass type I membrane protein

#### **Tissue Location**

Expressed by macrophages in various tissues. High levels are found in spleen, lymph node, perivascular macrophages in brain and lower levels in bone marrow, liver Kupffer cells and lamina propria of colon and lung. Also expressed by inflammatory macrophages in rheumatoid arthritis

### **SIGLEC1 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **SIGLEC1 Antibody (N-term) Blocking Peptide - Images**

### **SIGLEC1 Antibody (N-term) Blocking Peptide - Background**

SIGLEC1, encoded by a immunoglobulin superfamily gene, is a lectin-like adhesion molecule which binds glycoconjugate ligands on cell surfaces in a sialic acid-dependent manner. It is a type I transmembrane protein expressed only by a subpopulation of macrophages and is involved in mediating cell-cell interactions. Alternative splicing of the gene produces a variant encoding a protein isoform that is soluble rather than membrane-bound; however, the full-length nature of this variant has not been determined.

### **SIGLEC1 Antibody (N-term) Blocking Peptide - References**

Hartnell, A., et al., Blood 97(1):288-296 (2001).Nath, D., et al., Immunology 98(2):213-219 (1999).Mucklow, S., et al., Genomics 28(2):344-346 (1995).